News
XBIO
--
0.00%
--
60 Biggest Movers From Yesterday
Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
Benzinga · 5d ago
Healthcare names lead premarket gainers
Enochian Biosciences (ENOB) +143% on FDA acceptance of pre-IND request for potential HIV cure.MediaCo Holding (MDIA) +63%.iTeos Therapeutics (ITOS) +52%.Entasis Therapeutics Holdings (ETTX) +25%.Orphazyme A/S (ORPH) +23%.Luokung Technology (LKCO) +22%.Mere...
Seekingalpha · 6d ago
22 Stocks Moving in Monday's Pre-Market Session
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) rose 73.4% to $6.66 in pre-market trading. MediaCo, last week, named Rahsan-Rahsan Lindsay as Chief Executive Officer, effective July 1, 2021.
Benzinga · 6d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 06/11 20:32
BRIEF-Xenetic Biosciences Reports Net Loss Of $1.3 Mln For Quarter Ended March 31
reuters.com · 05/12 11:12
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
* Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States * Licensing Partners Leveraging PolyXen® Platform Technology Contin...
ACCESSWIRE · 05/12 11:00
10-Q: XENETIC BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS CAUTIONARY NOTE REGARDING...
Edgar Online - (EDG = 10Q, 10K) · 05/11 21:02
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ETFRAMINGHAM, MA / ACCESSWIRE /May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, ...
ACCESSWIRE · 05/10 13:30
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers  
Benzinga · 05/03 21:33
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 04/27 20:57
Gold Fields, Danimer Scientific among premarket losers' pack
AeroCentury (ACY) -46% after filing petition for Chapter 11Wave Life Sciences (WVE) -27% on setback for Huntington’s disease trial (updated).Trxade Group (MEDS) -21% on Q4 earnings release.Vinco Ventures (BBIG) -16% on providing update to ZASH Global Media...
Seekingalpha · 03/30 12:42
Xenetic Biosciences shares rise on approval to start XCART exploratory study
Xenetic Biosciences (XBIO) has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens.Shares up nearly 13%...
Seekingalpha · 03/29 12:39
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)
\- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States\- Study will evaluate the XCART process of neoantigen identifica...
ACCESSWIRE · 03/29 12:05
Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
* Driving development of XCART™ platform and leveraging academic collaborations through preclinical development * Recent clinical, regulatory and commercial advancements from licensing partners leveraging PolyXen® platform technology FRAMINGHAM, MA / ACCES...
ACCESSWIRE · 03/17 13:00
H.C. Wainwright Sticks to Its Buy Rating for Xenetic Biosciences (XBIO)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences (XBIO), with a price target of $5.00. The
SmarterAnalyst · 03/17 10:26
10-K: XENETIC BIOSCIENCES, INC.
Edgar Online - (EDG = 10Q, 10K) · 03/16 21:15
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 (ACCESSWIRE via COMTEX) -- FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"),...
ACCESSWIRE · 03/03 13:07
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likel...
Benzinga · 03/01 14:49
H.C. Wainwright Maintains a Buy Rating on Xenetic Biosciences (XBIO)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences (XBIO), with a price target of $5.00. The
SmarterAnalyst · 02/16 15:15
Xenetic Biosciences, Inc. Announces Partner's Filing Of Registration Dossier In Russia For Epolong Product Candidate That Utilizes Xenetic's PolyXen Platform Technology
PJSC Pharmsynthez is leveraging Xenetic's PolyXen® technology to improve the pharmacological properties of its Epolong product candidate pursuant to a royalty-bearing collaboration agreement Russian
Benzinga · 02/16 12:36
Webull provides a variety of real-time XBIO stock news. You can receive the latest news about Xenetic through multiple platforms. This information may help you make smarter investment decisions.
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The Company is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.